symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
EVAX,0.86,0.489121,116990,23789750,0,0.47-3.05,0.005,Evaxion Biotech A/S,USD,0001828253,US29970R1059,29970R105,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.evaxion-biotech.com,"Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in HÃ¸rsholm, Denmark.",Dr. Niels Iversen Moller M.D.,Healthcare,DK,63,45 53 53 18 50,Dr. Neergaards Vej,Horsholm,,2970,,0,https://financialmodelingprep.com/image-stock/EVAX.png,2021-02-05,False,False,True,True,False
